188582-62-9Relevant articles and documents
Liquid crystal compound
-
Paragraph 0358-0359, (2020/06/03)
PROBLEM TO BE SOLVED: To provide a compound exhibiting high dissolubility in a liquid crystal composition and high storage stability, and a liquid crystal composition and a liquid crystal display element containing the compound as a constitutional member. SOLUTION: There are provided 4-ethoxy-4'-methoxymethyl-2,3,3'-trifluorobiphenyl capable of being synthesized for example by reduction of a formyl group from 2-fluoro-4-bromobenzaldehyde, etherification and coupling with an organic boron compound like a following formula, and 4-ethoxy-4'-methoxypropyl-2,3,3'-trifluorobiphenyl capable of being synthesized by a similar method. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease
Rabal, Obdulia,Sánchez-Arias, Juan A.,Cuadrado-Tejedor, Mar,de Miguel, Irene,Pérez-González, Marta,García-Barroso, Carolina,Ugarte, Ana,Estella-Hermoso de Mendoza, Ander,Sáez, Elena,Espelosin, Maria,Ursua, Susana,Haizhong, Tan,Wei, Wu,Musheng, Xu,Garcia-Osta, Ana,Oyarzabal, Julen
supporting information, p. 506 - 524 (2018/03/21)
We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference versus class I HDACs) to decipher the contribution of HDAC isoforms to the positive impact of dua
IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
-
Paragraph 0051; 0052, (2016/08/29)
The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.